

primary studies - published RCT

Oral Reduced L-Glutathione Improves Growth in Pediatric Cystic Fibrosis Patients: A Randomized Clinical Trial.

Code: PM25633497

Year: 2015 Date: 2019

Author: Visca A

Study design (if review, criteria of inclusion for studies)

Post hoc analyses of pooled phase 3 data (NCT01807923, NCT01807949)

Participants

Patients with cystic fibrosis homozygous for F508del.

Interventions

lumacaftor/ivacaftor (LUM/IVA)

Outcome measures

Pulmonary exacerbations (PEX)

Main results

LUM (400mg q12h)/IVA (250mg q12h)-treated patients (n=369) experienced significantly fewer PEX vs placebo, regardless of threshold category. With LUM/IVA, PEX rate per patient per year was 0.60 for those with absolute change in ppFEV1>0 and 0.85 for those with absolute change

Authors' conclusions

LUM/IVA significantly reduced PEX, even in patients without early lung function improvement.

<http://dx.doi.org/10.1097/MPG.0000000000000738>

See also

J Pediatr Gastroenterol Nutr. 2015 Jan 28.

Keywords

Child; Adult; Adolescent; Aminophenols; CFTR Modulators; Genetic Predisposition to Disease; Orkambi; pharmacological_intervention; VX-770; ivacaftor; lumacaftor; VX-809;